Ondansetron Extended-Release (Shilpa Medicare)

昂丹司琼缓释注射液（印度素帕医药保健）

Report date: 2025/11/18 09:30:24

Base Information

Drug NameOndansetron Extended-Release (Shilpa Medicare)

Drug Alias NameOERISSMLINJ011SMLINJ-011

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerotonin 3 (5-HT3) receptor antagonists

TargetsSerotonin 3 (5-HT3) receptor

Therapy Area/IndicationsChemotherapy-induced nausea and vomiting

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesShilpa Medicare Ltd

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsChemotherapy-induced nausea and vomiting

Inactive IndicationsN/A

ATC CodeN/A